| Methods |
Randomised, double‐blind, placebo‐controlled cross‐over study |
| Participants |
Thirteen participants with progressive external ophthalmoplegia |
| Interventions |
10 g/day of whey‐based oral supplement or placebo for 30 days, then immediately proceed to next group |
| Outcomes |
Measurements of markers of free radical reducing capacity (advanced oxidation protein products (AOPP); ferric reducing antioxidant power (FRAP); glutathione (GSH) level). Serum lactate measured at various time points during cycle ergometry. Quality of life measured using SF‐36 questionnaire. Muscle power measured with MRC scale in various muscle groups |
| Notes |
AOPP, FRAP and GSH were statistically significantly increased in the treatment period. Lactate, quality of life, and muscle power were unchanged |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Method of randomisation not specified |
| Allocation concealment (selection bias) |
Unclear risk |
Method of allocation not specified |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
Incomplete outcome data adequately addressed |
| Selective reporting (reporting bias) |
Low risk |
All outcome measures in methods section were reported in results section |
| Other bias |
Unclear risk |
There was no washout period between trials which could potentially decrease the treatment effect |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
It is not specified whether the placebo had identical characteristics (appearance/taste) to the treatment |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Participants were randomly assigned to placebo or CoQ10 treatment |
